- Home
- INAB vs ATHA Comparison
INAB vs ATHA Comparison
Compare INAB & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INAB
- ATHA
- Stock Information
- Founded
- INAB 2016
- ATHA 2011
- Country
- INAB United States
- ATHA United States
- Employees
- INAB N/A
- ATHA N/A
- Industry
- INAB Biotechnology: Pharmaceutical Preparations
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- INAB Health Care
- ATHA Health Care
- Exchange
- INAB Nasdaq
- ATHA Nasdaq
- Market Cap
- INAB 14.5M
- ATHA 15.7M
- IPO Year
- INAB 2021
- ATHA 2020
- Fundamental
- Price
- INAB $2.16
- ATHA $0.37
- Analyst Decision
- INAB Strong Buy
- ATHA Buy
- Analyst Count
- INAB 2
- ATHA 4
- Target Price
- INAB $108.00
- ATHA $11.25
- AVG Volume (30 Days)
- INAB 151.7K
- ATHA 284.6K
- Earning Date
- INAB 08-07-2025
- ATHA 08-12-2025
- Dividend Yield
- INAB N/A
- ATHA N/A
- EPS Growth
- INAB N/A
- ATHA N/A
- EPS
- INAB N/A
- ATHA N/A
- Revenue
- INAB N/A
- ATHA N/A
- Revenue This Year
- INAB N/A
- ATHA N/A
- Revenue Next Year
- INAB N/A
- ATHA N/A
- P/E Ratio
- INAB N/A
- ATHA N/A
- Revenue Growth
- INAB N/A
- ATHA N/A
- 52 Week Low
- INAB $2.05
- ATHA $0.22
- 52 Week High
- INAB $26.39
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- INAB 38.73
- ATHA 45.08
- Support Level
- INAB $2.12
- ATHA $0.34
- Resistance Level
- INAB $2.57
- ATHA $0.51
- Average True Range (ATR)
- INAB 0.14
- ATHA 0.04
- MACD
- INAB 0.04
- ATHA -0.01
- Stochastic Oscillator
- INAB 7.24
- ATHA 10.91
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.